AngelMD

Founded in 2021, OraQ AI is a Canadian company that develops a clinical decision support system. This system empowers patients by utilizing artificial intelligence and machine learning to improve dental care through advanced assessments, risk profiling, and holistic treatment strategies.

Raydiant Oximetry is a medical device company developing a non-invasive fetal monitoring device that measures fetal oxygen levels to improve outcomes for mothers and babies during childbirth and to reduce unnecessary cesarean sections. Founded in 2015 and based in California, the company aims to provide low-cost, real-time monitoring of fetal oxygenation during labor, enabling clinicians to assess fetal well-being and minimize intervention.

Neumentum, Inc. is a pharmaceutical company focused on the development and commercialization of non-opioid analgesic and neurology products. Founded in 2017 and headquartered in Palo Alto, California, Neumentum aims to provide safe and effective alternatives for pain management that mitigate the risks associated with opioid use, such as misuse and addiction. The company is advancing multiple non-opioid drug candidates, including two phase 3-ready injectable products specifically designed for acute postsurgical pain. Through its innovative platform, Neumentum is committed to addressing unmet medical needs in both hospital and retail markets, offering viable treatment options for patients experiencing acute and chronic pain.

Access Vascular, Inc. is a medical technology company based in Bedford, Massachusetts, founded in 2015. The company specializes in developing innovative venous access devices that utilize advanced hydrogel materials to significantly reduce thrombosis accumulation, a common complication in intravenous therapy. Their product line includes peripherally inserted central catheters, hemodialysis devices, implantable ports, and drug delivery systems. By addressing critical issues such as occlusions and infections, Access Vascular aims to enhance clinical outcomes, lower healthcare costs, and improve patient experiences. The company's HydroPICC catheter exemplifies their commitment to advancing venous access technology, as it offers superior performance over existing solutions, thereby increasing catheter dwell time and minimizing associated complications.

Raydiant Oximetry is a medical device company developing a non-invasive fetal monitoring device that measures fetal oxygen levels to improve outcomes for mothers and babies during childbirth and to reduce unnecessary cesarean sections. Founded in 2015 and based in California, the company aims to provide low-cost, real-time monitoring of fetal oxygenation during labor, enabling clinicians to assess fetal well-being and minimize intervention.

Iterion Therapeutics, Inc. is a clinical-stage biotechnology company based in Houston, Texas, focused on developing innovative therapeutics for cancer treatment. Established in 2010, the company specializes in targeted cancer therapies, with its lead product, Tegavivint, serving as a potent and selective inhibitor of the Wnt/b-catenin signaling pathway. This pathway is known to play a critical role in various cancer-related processes, including cell proliferation and immune evasion. Tegavivint has demonstrated pre-clinical efficacy in several cancer models, such as desmoid tumors, acute myeloid leukemia, osteosarcoma, and various solid tumors. Iterion Therapeutics is actively enrolling patients in a Phase I clinical study of Tegavivint for desmoid tumors at multiple clinical centers across the United States and Canada.

LifeSprout is developing the next generation of synthetic soft tissue substitutes for aesthetic and reconstructive medicine. They offer revolutionary products for aesthetic and regenerative medicine. They have created a platform that looks and behaves like the body’s own tissues. The company is turning this into a suite of products for millions of patients each year with soft tissue losses from aging, cancer, and metabolic disease.

Sensulin develops a glucose-responsive insulin using Agglomerated Vesicle Technology, a liposome-based drug delivery platform that uses stimulus-responsive linkages to encapsulate and release drugs. The company aims to create a true once-daily insulin that mimics a healthy pancreas for type 1 and type 2 diabetes, potentially eliminating the need for basal and prandial insulin and reducing glucose monitoring. Based in Oklahoma City, it was founded in 2011.

Fibralign develops advanced biomedical devices using its proprietary Nanoweave® scaffolding technology. Its first product, BioBridge® Collagen Matrix, is undergoing clinical studies for treating secondary lymphedema and ischemia, with potential applications in stem cell and gene therapy delivery.

Access Vascular, Inc. is a medical technology company based in Bedford, Massachusetts, founded in 2015. The company specializes in developing innovative venous access devices that utilize advanced hydrogel materials to significantly reduce thrombosis accumulation, a common complication in intravenous therapy. Their product line includes peripherally inserted central catheters, hemodialysis devices, implantable ports, and drug delivery systems. By addressing critical issues such as occlusions and infections, Access Vascular aims to enhance clinical outcomes, lower healthcare costs, and improve patient experiences. The company's HydroPICC catheter exemplifies their commitment to advancing venous access technology, as it offers superior performance over existing solutions, thereby increasing catheter dwell time and minimizing associated complications.

Otomagnetics develops and manufactures a magnetic injection delivery system designed to non-invasively administer therapies to various compartments of the inner and middle ear, as well as the eye and skin. Incorporated in 2012, the company is headquartered in Rockville, Maryland.

Qool Therapeutics, Inc. is focused on developing non-invasive temperature management therapies aimed at inducing therapeutic hypothermia. Incorporated in 2005 and headquartered in Menlo Park, California, the company offers innovative solutions designed to preserve cells, improve patient quality of life, and extend lifespan. Its specialized devices provide an effective system for tissue preservation by influencing various cell functions, which helps slow inflammation, limit cell damage, and reduce oxygen requirements for cells. This technology enables medical professionals to offer a safe and straightforward option for patients requiring temperature management.

Noninvasix, Inc., established in 2007, is a medical technology company based in Galveston, Texas. It develops non-invasive precision oximetry systems designed to measure oxygen sufficiency within organs and veins without the need for invasive catheters. The company's primary focus is on monitoring brain oxygenation in preterm babies within newborn intensive care units (NICUs). Noninvasix has raised over $6.8 million in funding, including a seed round in late 2021, and has been supported by grants from the NIH and DOD totaling $6 million. The company's technology has been clinically validated and is protected by a robust IP portfolio comprising 9 U.S. and 8 global patents. Noninvasix has participated in prestigious accelerator programs such as Philips Healthworks and TMCx, and its innovations have earned multiple awards.

KPI Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, specializing in the development of therapies for unmet medical needs in the fields of autoimmunity and chronic pain. Founded in 2013, the company is actively working on several therapeutic candidates, including dalazatide, KPI-150, and KPI-190, aimed at treating systemic autoimmune diseases such as lupus, as well as CSP conopeptide for chronic pain management. KPI Therapeutics collaborates with various partners, including Kineta, Inc., Chimera Biotec, and the University of Washington School of Medicine, to enhance drug development and improve access to innovative medicines. The company is committed to accelerating the transition of promising drug candidates through critical stages of development, ultimately addressing significant patient needs in healthcare.

Kineta is a clinical-stage biotechnology company based in Seattle, Washington. Founded in 2007, it focuses on developing immunology-based therapies for oncology and virology. Notable products include KCP-506 for chronic pain treatment and LHF-535 for antiviral therapy against viruses like Lassa. Kineta also has drug development programs targeting RIG-I and VISTA for cancer immunotherapy.